- Home
- ACIU
ACIU
AC Immune SA
as 12-20-2024 4:00pm EST
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
| Founded: | 2003 | Country: | Switzerland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 332.4M | IPO Year: | 2016 |
| Target Price: | $12.00 | AVG Volume (30 days): | 134.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.49 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.25 - $5.14 | Next Earning Date: | 11-05-2024 |
| Revenue: | $48,505,404 | Revenue Growth: | 4097200.00% |
| Revenue Growth (this year): | 85.33% | Revenue Growth (next year): | 80.69% |
Latest AC Immune SA News
ACIU Breaking Stock News: Dive into ACIU Ticker-Specific Updates for Smart Investing
TipRanks
11 days ago
AC Immune announces interim safety, tolerability data from ABATE Phase 1b/2
GlobeNewswire
12 days ago
AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome
Pharmaceutical Technology
a month ago
AC Immune’s stock jumps after Parkinson’s therapy shows signs of benefit
TipRanks
a month ago
AC Immune reports interim results from Phase 2 trial of ACI-7104.056
MT Newswires
a month ago
Sector Update: Health Care Stocks Lower Thursday Afternoon
MT Newswires
a month ago
AC Immune Shares Gain Following Positive Clinical Results of Potential Parkinson's Treatment
GlobeNewswire
a month ago
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
GlobeNewswire
a month ago
AC Immune to Present at the Jefferies 2024 London Healthcare Conference
Compare ACIU vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ACIU AC Immune SA - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.